Surgery Partners (SGRY) to Release Quarterly Earnings on Tuesday

Posted by Brenda Bartman on May 4th, 2026

Surgery Partners (NASDAQ:SGRY – Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $797.6880 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Surgery Partners (NASDAQ:SGRY – Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analyst estimates of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period last year, the firm posted $0.44 EPS. On average, analysts expect Surgery Partners to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Surgery Partners Trading Up 1.7%

NASDAQ:SGRY traded up $0.25 during trading hours on Monday, hitting $14.52. The company had a trading volume of 154,663 shares, compared to its average volume of 1,501,788. Surgery Partners has a 1 year low of $11.41 and a 1 year high of $24.18. The company has a market cap of $1.90 billion, a P/E ratio of -23.40 and a beta of 1.99. The company has a 50-day moving average of $13.39 and a 200 day moving average of $15.65. The company has a current ratio of 1.87, a quick ratio of 1.71 and a debt-to-equity ratio of 1.15.

Surgery Partners announced that its board has initiated a stock buyback program on Thursday, February 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to purchase up to 9.7% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

SGRY has been the subject of several analyst reports. TD Cowen dropped their price target on shares of Surgery Partners from $28.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. US Capital Advisors set a $21.00 price objective on Surgery Partners in a report on Wednesday, March 11th. Barclays lowered their price objective on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 3rd. Benchmark restated a “buy” rating on shares of Surgery Partners in a research report on Tuesday, March 3rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 11th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.00.

Check Out Our Latest Analysis on SGRY

Insider Transactions at Surgery Partners

In related news, insider Jennifer Baldock sold 10,082 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $13.70, for a total transaction of $138,123.40. Following the completion of the transaction, the insider owned 332,272 shares of the company’s stock, valued at approximately $4,552,126.40. This trade represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David T. Doherty sold 14,574 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $13.84, for a total value of $201,704.16. Following the completion of the sale, the chief financial officer directly owned 88,803 shares in the company, valued at approximately $1,229,033.52. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 96,896 shares of company stock worth $1,284,058. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Surgery Partners

Several hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in Surgery Partners by 3.8% in the 4th quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company’s stock valued at $209,162,000 after acquiring an additional 501,401 shares in the last quarter. Pentwater Capital Management LP boosted its stake in shares of Surgery Partners by 66.9% in the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Surgery Partners by 1.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,906,580 shares of the company’s stock valued at $75,808,000 after purchasing an additional 46,365 shares in the last quarter. UBS Group AG grew its holdings in shares of Surgery Partners by 50.6% in the third quarter. UBS Group AG now owns 3,690,922 shares of the company’s stock valued at $79,872,000 after purchasing an additional 1,239,549 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Surgery Partners by 528.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock worth $30,277,000 after buying an additional 1,647,714 shares during the period.

Surgery Partners Company Profile

(Get Free Report)

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.